Literature DB >> 25603954

Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study.

Susanna Sainio1, Irmeli Nupponen, Malla Kuosmanen, Ansa Aitokallio-Tallberg, Eeva Ekholm, Erja Halmesmäki, Maija-Riitta Orden, Pertti Palo, Tytti Raudaskoski, Aydin Tekay, Jarno Tuimala, Jukka Uotila, Vedran Stefanovic.   

Abstract

OBJECTIVE: Outcome after intrauterine transfusions due to severe hemolytic disease of the fetus and newborn.
DESIGN: Nationwide population-based retrospective cohort study.
SETTING: All women treated with intrauterine transfusions for hemolytic disease of the fetus and newborn in Finland in 2003-2012. POPULATION: 339 intrauterine transfusions, performed in 104 pregnancies of 84 women.
METHODS: Information on antenatal screening of red cell antibodies and red cell units issued for intrauterine transfusion was obtained from the Finnish Red Cross Blood Service database, and obstetric and neonatal data from hospital records. MAIN OUTCOME MEASURES: Procedure-related complications, perinatal mortality, neonatal morbidity.
RESULTS: Overall survival was 94.2% (95% confidence interval 89.7-98.7). There were four fetal and two neonatal deaths. Procedure-related fetal loss rate was 1.2% (95% confidence interval 0.04-2.4) per procedure and 3.8% (95% confidence interval 0.1-7.5) per pregnancy. Of the four procedure-related losses, three were due to technically difficult intrauterine transfusions causing infection and preterm birth. Of the live born infants, 19% (95% confidence interval 11.3-26.7) were born before 32 weeks' gestation. The incidence of severe neonatal morbidity (respiratory distress syndrome, severe cerebral injury, sepsis) was 22.2% (95% confidence interval 13.4-30.2). Poor outcome (death, severe neonatal morbidity) was negatively associated with gestational age at first transfusion (p = 0.001) and at birth (p = 0.00006). Follow-up of the infants was too incomplete to assess the neurodevelopmental outcome.
CONCLUSIONS: Although overall survival is comparable with previous studies, our concern is procedure-related infections and preterm births. Close collaboration between the university hospitals is needed to ensure timely treatment, operator skills and systematic follow-up of the children.
© 2015 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Hemolytic disease of the fetus and newborn; fetal anemia; intrauterine transfusion; neonate; perinatal outcome

Mesh:

Year:  2015        PMID: 25603954     DOI: 10.1111/aogs.12590

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Intrauterine Fetal Blood Transfusion: Descriptive study of the first four years' experience in Oman.

Authors:  Arwa Z Al-Riyami; Mouza Al-Salmani; Sabria N Al-Hashami; Sabah Al-Mahrooqi; Ali Al-Marhoobi; Sumaiya Al-Hinai; Saif Al-Hosni; Sathiya M Panchatcharam; Zainab A Al-Arimi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

2.  Efficacy of Antenatal Intravenous Immunoglobulin Treatment in Pregnancies at High Risk due to Alloimmunization to Red Blood Cells.

Authors:  Beate Mayer; Larry Hinkson; Wiebke Hillebrand; Wolfgang Henrich; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2018-10-31       Impact factor: 3.747

3.  Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures.

Authors:  C Zwiers; I T M Lindenburg; F J Klumper; M de Haas; D Oepkes; I L Van Kamp
Journal:  Ultrasound Obstet Gynecol       Date:  2017-08       Impact factor: 7.299

4.  Management and outcome of pregnancies in women with red cell isoimmunization: a 15-year observational study from a tertiary care university hospital.

Authors:  María Ángeles Sánchez-Durán; María Teresa Higueras; Cecilia Halajdian-Madrid; Mayte Avilés García; Andrea Bernabeu-García; Nerea Maiz; Nuria Nogués; Elena Carreras
Journal:  BMC Pregnancy Childbirth       Date:  2019-10-15       Impact factor: 3.007

5.  The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization.

Authors:  Carolien Zwiers; Dick Oepkes; Enrico Lopriore; Frans J Klumper; Masja de Haas; Inge L van Kamp
Journal:  Prenat Diagn       Date:  2018-09-27       Impact factor: 3.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.